Docket No.: 2026-4003US3

 determining a dosage, said dosage comprising 5-15 mCi ⁹⁰Y-conjugated anti-Tac in a total amount of 2-20 mg anti-Tac, wherein the dose is 2 mg total anti-Tac if said patient has sIL-2R levels of less than 2,000 units/ml, the dose is 5 mg total anti-Tac if said patient has sIL-2R levels of 2,000 - 10,000 units/ml, the dose is 10 mg of total anti-Tac if the patient has sIL-2R levels of 10,000 - 50,000 units/ml, and the dose is 20 mg of total anti-Tac if said patient has sIL-2R levels of greater that 50,000 units/ml; and administering said dosage to said patient to eliminate disease-associated Tac-positive cells.

REMARKS

Applicant respectfully requests favorable reconsideration in view of the herewith presented amendment and remarks. Applicant gratefully acknowledges the telephone interview on March 18, 1999 with the Examiner, Examiner Chan and Dr. Richard Schwartz and the undersigned. In this interview, it was agreed that a claim as set forth above would constitute patentable subject matter.

Claim 27 is pending in the instant patent application.

As agreed during the telephone interview, none of the previously cited prior art teaches or suggests the method as presently claimed. Thus, in view of the new claim, applicant believes the previous rejections under 35 U.S.C §§102 and 103 are rendered moot.

Docket No.: 2026-4003US3

Also enclosed, as requested by the Examiner, is a declaration from the inventor

stating that the claimed subject matter was not published or publicly disclosed on or before the

filing date of the present application..

No additional fee is believed to be necessary.

The Commissioner is hereby authorized to charge any additional fees which may

be required for this response, or credit any overpayment to Deposit Account No. 13-4500, Order

No. 2026-4003US3.

In the event that an extension of time is required, or which may be required in

addition to that requested in a petition and for an extension of time, the Commissioner is

requested to grant a petition for that extension of time which is required to make this response

timely and is hereby authorized to charge any fee for such an extension of time or credit any

overpayment for an extension of time to Deposit Account No. 13-4500, Order No. 2026-

4003US3. A DUPLICATE COPY OF THIS SHEET IS ATTACHED.

Respectfully submitted,

MORGAN & FINNEGAN, L.L.P.

Dated: March 23 1999

Dorothy R. Auth

Registration No. 36,434

MORGAN & FINNEGAN 345 Park Avenue New York, New York 10154 (212) 758-4800 (212 751-6849 Telecopier